Peter O’Donnell - Profile and Journalist Details
Find journalists that align with your industry, location and vision. Unlock Peter O’Donnell's full journalist profile, including location, coverage topics, current employer, biography and preferences. Sign up today and start building journalist relationships that fuel your startup's growth.
Get connected with journalists today
Peter O’Donnell
Verified
Brussels Correspondent, APM Health Europe
Brussels
Beats
business content tech content, -, and lifestyle content and local news. human interest, mental health climate and environmental justice., International
ask me and I will let you know.
Content
Efficacy and safety of pembrolizumab in patients with advanced urothelial carcinoma deemed potentially ineligible for platinum‐containing chemotherapy: Post hoc analysis of KEYNOTE‐052 and LEAP‐011
By Peter O’Donnell Verified, Yohann Loriot, Tibor Csöszi, Nobuaki Matsubara| Wiley Online Library Verified INTRODUCTION Approximately 30%–50% of patients with advanced urothelial carcinoma (UC) are ineligible to receive cisplatin-based chemotherapy because of baseline characteristics such as advanced age, renal dysfunction, poor performance status, and other medical comorbidities.1, 2 Although numerous patients in this population can still receive carboplatin-based treatment, many are deemed ineligible for any cytotoxic platinum-based chemotherapy by their treating physicians.3, 4 Because no...
By Peter O’Donnell Verified| Ticpharma@ La Fédération européenne des industries et associations pharmaceutiques (EFPIA) est l'une des 32 organisations européennes du secteur de la santé ayant rencontré des fonctionnaires de l'Union européenne (UE), des représentants des prochaines présidences de l'UE (Belgique puis Hongrie) et l'eurodéputé croate chef de file du Parlement européen sur la proposition, Tomislav Sokol, le 6 septembre.
Efficacy and safety of pembrolizumab in patients with advanced urothelial carcinoma deemed potentially ineligible for platinum‐containing chemotherapy: Post hoc analysis of KEYNOTE‐052 and LEAP‐011
By Peter O’Donnell Verified, Yohann Loriot, Tibor Csöszi, Nobuaki Matsubara| Wiley Online Library Verified INTRODUCTION Approximately 30%–50% of patients with advanced urothelial carcinoma (UC) are ineligible to receive cisplatin-based chemotherapy because of baseline characteristics such as advanced age, renal dysfunction, poor performance status, and other medical comorbidities.1, 2 Although numerous patients in this population can still receive carboplatin-based treatment, many are deemed ineligible for any cytotoxic platinum-based chemotherapy by their treating physicians.3, 4 Because no...
Company Info
APM Health Europe
Ile-de-France, France
'+44 20 7324 2327